Tissue Models and Drug Screening Europe
06 May 2014 - 07 May 2014 - Berlin, Germany
Over the years, three-dimensional (3D) models have become more favored over two-dimensional models (2D) because they better mimic the in vivo environment. Though 3D models have the potential to reduce failure in early stage drug discovery, there are still many questions to be answered: What are the gaps that still exist between 3D and 2D models? How will we conduct research to fill those gaps and what technological developments are needed?